The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Dengue Fever: Causes, Complications, and Vaccine Strategies
Open accessAbstract
Dengue is a highly endemic infectious disease of the tropical countries and is rapidly becoming a global burden. It is caused by any of the 4 serotypes of dengue virus and is transmitted within humans through female Aedes mosquitoes. Dengue disease varies from mild fever to severe conditions of dengue hemorrhagic fever and shock syndrome. Globalization, increased air travel, and unplanned urbanization have led to increase in the rate of infection and helped dengue to expand its geographic and demographic distribution. Dengue vaccine development has been a challenging task due to the existence of four antigenically distinct dengue virus serotypes, each capable of eliciting cross-reactive and disease-enhancing antibody response against the remaining three serotypes. Recently, Sanofi Pasteur’s chimeric live-attenuated dengue vaccine candidate has been approved in Mexico, Brazil, and Philippines for usage in adults between 9 and 45 years of age. The impact of its limited application to the public health system needs to be evaluated. Simultaneously, the restricted application of this vaccine candidate warrants continued efforts in developing a dengue vaccine candidate which is additionally efficacious for infants and naïve individuals. In this context, alternative strategies of developing a designed vaccine candidate which does not allow production of enhancing antibodies should be explored, as it may expand the umbrella of efficacy to include infants and naïve individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global distribution and burden of dengue
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., et al. (2013) · Nature · doi:10.1038/nature12060 · Cited by 10,037 · cited 1×
“A recent dengue distribution model has estimated 390 million dengue infections annually, out of which 96million cases occurred apparently [6, 7].”
Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus
Brady, O. J., Gething, P. W., Bhatt, S., Messina, J. P., Brownstein, J. S., Hoen, A. G., Moyes, C. L., Farlow, A. W., Scott, T. W., & Hay, S. I. (2012) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001760 · Cited by 1,864
Kuhn, R. J., Zhang, W., Rossmann, M. G., Pletnev, S. V., Corver, J., Lenches, E., Jones, C. T., Mukhopadhyay, S., Chipman, P. R., Strauss, E. G., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00660-8 · Cited by 1,563
The global burden of dengue: an analysis from the Global Burden of Disease Study 2013
Stanaway, J. D., Shepard, D. S., Undurraga, E. A., Halasa, Y. A., Coffeng, L. E., Brady, O. J., Hay, S. I., Bedi, N., Bensenor, I. M., Castañeda-Orjuela, C. A., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00026-8 · Cited by 1,124
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
Hadinegoro, S. R., Arredondo-García, J. L., Capeding, M. R., Deseda, C., Chotpitayasunondh, T., Dietze, R., Hj Muhammad Ismail, H. I., Reynales, H., Limkittikul, K., Rivera-Medina, D. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506223 · Cited by 1,077
Capeding, M. R., Tran, N. H., Hadinegoro, S. R. S., Ismail, H. I. H. M., Chotpitayasunondh, T., Chua, M. N., Luong, C. Q., Rusmil, K., Wirawan, D. N., Nallusamy, R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61060-6 · Cited by 973
Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans
Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S., Limpitikul, W., Puttikhunt, C., Edwards, C., Duangchinda, T., Supasa, S., et al. (2010) · Science · doi:10.1126/science.1185181 · Cited by 943
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
Villar, L., Dayan, G. H., Arredondo-García, J. L., Rivera, D. M., Cunha, R., Deseda, C., Reynales, H., Costa, M. S., Morales-Ramírez, J. O., Carrasquilla, G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411037 · Cited by 942
Sabchareon, A., Wallace, D., Sirivichayakul, C., Limkittikul, K., Chanthavanich, P., Suvannadabba, S., Jiwariyavej, V., Dulyachai, W., Pengsaa, K., Wartel, T. A., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61428-7 · Cited by 818
Human skin Langerhans cells are targets of dengue virus infection
Wu, S.-J. L., Grouard-Vogel, G., Sun, W., Mascola, J. R., Brachtel, E., Putvatana, R., Louder, M. K., Filgueira, L., Marovich, M. A., Wong, H. K., et al. (2000) · Nature Medicine · doi:10.1038/77553 · Cited by 666
Weiskopf, D., Angelo, M. A., de Azeredo, E. L., Sidney, J., Greenbaum, J. A., Fernando, A. N., Broadwater, A., Kolla, R. V., De Silva, A. D., de Silva, A. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305227110 · Cited by 615
Jessie, K., Fong, M. Y., Devi, S., Lam, S. K., & Wong, K. T. (2004) · The Journal of Infectious Diseases · doi:10.1086/383043 · Cited by 613
Malavige, G. N., Fernando, S., Fernando, D. J., & Seneviratne, S. L. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.019638 · Cited by 551
Modhiran, N., Watterson, D., Muller, D. A., Panetta, A. K., Sester, D. P., Liu, L., Hume, D. A., Stacey, K. J., & Young, P. R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3863 · Cited by 549
Beatty, P. R., Puerta-Guardo, H., Killingbeck, S. S., Glasner, D. R., Hopkins, K., & Harris, E. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3787 · Cited by 509
Immune Response to Dengue Virus and Prospects for a Vaccine
Murphy, B. R., & Whitehead, S. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101315 · Cited by 448
Variable Surface Epitopes in the Crystal Structure of Dengue Virus Type 3 Envelope Glycoprotein
Modis, Y., Ogata, S., Clements, D., & Harrison, S. C. (2005) · Journal of Virology · doi:10.1128/jvi.79.2.1223-1231.2005 · Cited by 429
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions
de Alwis, R., Smith, S. A., Olivarez, N. P., Messer, W. B., Huynh, J. P., Wahala, W. M. P. B., White, L. J., Diamond, M. S., Baric, R. S., Crowe, J. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200566109 · Cited by 390
Dengue/Dengue Haemorrhagic Fever: History and Current Status
Gubler, D. J. (2006) · Novartis Foundation Symposia · doi:10.1002/0470058005.ch2 · Cited by 348
Chen, R., & Vasilakis, N. (2011) · Viruses · doi:10.3390/v3091562 · Cited by 301
Kirkpatrick, B. D., Whitehead, S. S., Pierce, K. K., Tibery, C. M., Grier, P. L., Hynes, N. A., Larsson, C. J., Sabundayo, B. P., Talaat, K. R., Janiak, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1517 · Cited by 262
Guirakhoo, F., Pugachev, K., Zhang, Z., Myers, G., Levenbook, I., Draper, K., Lang, J., Ocran, S., Mitchell, F., Parsons, M., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4761-4775.2004 · Cited by 253
Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers
Fibriansah, G., Ibarra, K. D., Ng, T.-S., Smith, S. A., Tan, J. L., Lim, X.-N., Ooi, J. S. G., Kostyuchenko, V. A., Wang, J., de Silva, A. M., et al. (2015) · Science · doi:10.1126/science.aaa8651 · Cited by 230
Aedes albopictus and the reemergence of Dengue
Rezza, G. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-72 · Cited by 225
In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection
de Alwis, R., Beltramello, M., Messer, W. B., Sukupolvi-Petty, S., Wahala, W. M. P. B., Kraus, A., Olivarez, N. P., Pham, Q., Brian, J., Tsai, W.-Y., et al. (2011) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001188 · Cited by 216
Barniol, J., Gaczkowski, R., Barbato, E. V., da Cunha, R. V., Salgado, D., Martínez, E., Segarra, C. S., Pleites Sandoval, E. B., Mishra, A., Laksono, I. S., et al. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-106 · Cited by 212
Guirakhoo, F., Kitchener, S., Morrison, D., Forrat, R., McCarthy, K., Nichols, R., Yoksan, S., Duan, X., Ermak, T. H., Kanesa-Thasan, N., et al. (2006) · Human Vaccines · doi:10.4161/hv.2.2.2555 · Cited by 197
Whitehead, S. S. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1115727 · Cited by 176
Putnak, R. J., Barvir, D., Burrous, J., et al. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.6.1176 · Cited by 169
Morrison, D., Legg, T. J., Billings, C. W., Forrat, R., Yoksan, S., & Lang, J. (2010) · The Journal of Infectious Diseases · doi:10.1086/649916 · Cited by 165
Protective and immunological behavior of chimeric yellow fever dengue vaccine
Halstead, S. B., & Russell, P. K. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.004 · Cited by 161
Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial
Beckett, C. G., Tjaden, J., Burgess, T., Danko, J. R., Tamminga, C., Simmons, M., Wu, S.-J., Sun, P., Kochel, T., Raviprakash, K., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.11.050 · Cited by 160
Osorio, J. E., Velez, I. D., Thomson, C., Lopez, L., Jimenez, A., Haller, A. A., Silengo, S., Scott, J., Boroughs, K. L., Stovall, J. L., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70811-4 · Cited by 158
Whitehead, S. S., Falgout, B., Hanley, K. A., Blaney, J. E., Markoff, L. J., & Murphy, B. R. (2002) · Journal of Virology · doi:10.1128/jvi.77.2.1653-1657.2003 · Cited by 154
Bhamarapravati, N., Yoksan, S., Chayaniyayothin, T., Angsubphakorn, S., & Bunyaratvej, A. (1987) · Europe PMC (PubMed Central) · Cited by 150
T-Cell Immunity to Infection with Dengue Virus in Humans
Weiskopf, D., & Sette, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00093 · Cited by 150
Raviprakash, K. S., Wang, D., Ewing, D. F., Holman, D. H., Block, K., Woraratanadharm, J., Chen, L., Hayes, C., Dong, J. Y., & Porter, K. R. (2008) · Journal of Virology · doi:10.1128/jvi.02724-07 · Cited by 126
HERMIDA, L., Bernardo, L., MARTIN, J., Alvarez, M., PRADO, I., LOPEZ, C., Sierra, B., MARTINEZ, R., Rodríguez, R., & Zulueta, A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.036 · Cited by 123
Mouse Models to Study Dengue Virus Immunology and Pathogenesis
Zellweger, R. L. M., & Shresta, S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00151 · Cited by 116
Efficacy of a Tetravalent Chimeric Dengue Vaccine (DENVax) in Cynomolgus Macaques
Osorio, J. E., Brewoo, J. N., Silengo, S. J., et al. (2011) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2011.10-0592 · Cited by 111
Animal models for studying dengue pathogenesis and therapy
Chan, K. W. K., Watanabe, S., Kavishna, R., Alonso, S., & Vasudevan, S. G. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.08.013 · Cited by 91
Progress in the Identification of Dengue Virus Entry/Fusion Inhibitors
Guardia, C. D. L., & Lleonart, R. (2014) · BioMed Research International · doi:10.1155/2014/825039 · Cited by 76
Govindarajan, D., Meschino, S., Guan, L., Clements, D. E., ter Meulen, J. H., Casimiro, D. R., Coller, B.-A., & Bett, A. J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.06.067 · Cited by 75
Watanabe, S., Chan, K. W. K., Wang, J., Rivino, L., Lok, S., & Vasudevan, S. G. (2015) · Journal of Virology · doi:10.1128/jvi.00216-15 · Cited by 73
Current progress in dengue vaccines
Wan, S.-W., Lin, C., Wang, S., Chen, Y., Yeh, T., Liu, H., Anderson, R., & Lin, Y.-S. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-37 · Cited by 73
Development of dengue DNA vaccines
Danko, J., Beckett, C. G., & Porter, K. R. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.019 · Cited by 71
Preclinical and clinical development of a dengue recombinant subunit vaccine
Manoff, S. B., George, S. L., Bett, A. J., Yelmene, M. L., Govindarajan, D., Eggemeyer, L. M., Sausser, M., Dubey, S. A., Casimiro, D. R., Clements, D. E., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.101 · Cited by 70
Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine
Porter, K. R., Ewing, D. F., Chen, L., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.10.085 · Cited by 68
Dengue vaccines: Challenges, development, current status and prospects
Ghosh, A., & Dar, L. (2015) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.148369 · Cited by 58
Suzuki, R., Winkelmann, E., & Mason, P. W. (2008) · Journal of Virology · doi:10.1128/jvi.01891-08 · Cited by 49
White, L., Mattocks, M. D., Whitmore, A. C., Williams, B. M., de Silva, A., & Johnston, R. E. (2007) · Journal of Virology · doi:10.1128/jvi.00512-07 · Cited by 49
Dayan, G. H., Thakur, M. K., Boaz, M. J., & Johnson, C. L. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.08.088 · Cited by 44
Cited by
Digital Health Interventions in Dengue Surveillance to Detect and Predict Outbreak: A Scoping Review
Salim, M. F., Satoto, T. B. T., ., D., & Daniel, D. (2024) · The Open Public Health Journal · doi:10.2174/0118749445283264240116070726 · Cited by 13
Metadata
- Authors
- Khetarpal, N., & Khanna, I.
- Venue
- Journal of Immunology Research
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-14
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- OpenAlex
- W2479953748
- Cited by
- 363
- References
- 52
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.